Insomnia Market: Industry Analysis and Forecast (2021-2027) by Treatment Type, Non-pharmacological Treatment, and Region

Global Insomnia Market size was valued at US$ 4.82 Bn in 2020 and the total revenue is expected to grow at 4.2 % through 2021 to 2027, reaching nearly US$ 6.43 Bn.

Global Insomnia Market Overview:

Insomnia is a sleeping problem that affects people of all ages. Insomnia is also a term used to describe someone who has problems sleeping. This might exist in its own right or in combination with other psychological problems. Insomnia is more common in women than in men, and it is more likely to occur throughout life stages such as pregnancy and after childbirth, as well as the menopausal cycle. The specific origin of sleeplessness, however, remains a secret. Global Insomnia Market To know about the Research Methodology :- Request Free Sample Report 2020 is considered as a base year to forecast the market from 2021 to 2027. 2020’s market size is estimated on real numbers and outputs of the key players and major players across the globe. Past five years trends are considered while forecasting the market through 2027. 2020 is a year of exception and analyzed specially with the impact of lockdown by region.

Global Insomnia Market Dynamics:

An increasing in the launch of new sleep-inducing drugs, devices, and treatments is anticipated to drive the insomnia market growth. For example, the Insomnia Clinic in Bloomsbury has developed a new treatment for insomnia. The clinical trials for the Insomnia showed positive results where 80% of the patients displayed remarkable improvements. Likewise, Eisai Inc has developed a drug called lemborexant (dual orexin receptor antagonist), adual orexin receptor antagonist that anticipated to be effective for the treatment of the older population with insomnia. Positive results and low price of devices are predictable to be the major factors promoting demand for devices. Insomnia therapeutic devices have started gaining traction in developed countries such as Norway, Switzerland, Australia and Ireland. Medical devices have benefits like the fast onset of sleep and longer sleep maintenance among patients who have negative results through drugs. New technical devices like Alpha-Stim AID, Ebb Insomnia Therapy, and Fisher Wallace Stimulator have already received approvals from FDA. The Lemborexant, a novel Orexin Receptor Antagonist (ORA) by Eisai is anticipated to be launched in the early phase during forecast period. Manufacturers in the Insomnia are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Insomnia Market Segment Analysis:

The global Insomnia Market is segmented by Treatment Type and Non-pharmacological Treatment. Based on Treatment Type, the global Insomnia market is segmented into Non-pharmacological Treatment and Pharmacological Treatment. The pharmacological treatment is further sub-segmented into prescription sleep aids and over-the-counter sleep aids. The over-the-counter sleep aids is expected to grow at a highest CAGR of xx% in the global insomnia market during the forecast period. As comparison to prescription sleep medications, due to its easy accessibility and lower cost As per research statistics, utilising over-the-counter sleep medications will save a patient up to USD 47 each week.

Global Insomnia MarketGlobal Insomnia Market Regional Insights:

North America dominate the global Insomnia market during the forecast period 2021-2027. North America held the largest market share xx% in 2020. Asia Pacific without Japan is also expected to be a dominant region for the insomnia market’s growth. The reason for this is attributable to the increasing shift-related work in this region causing numerous sleep disorders. The rising urban population in this region has also driven the market’s expansion. Indonesia, India, and China are expected to be leading regions for the market’s growth in this region. According to Centers for Disease Control and Prevention (CDCP), approximately xx million adults in the United State suffered from insomnia disease. This is a result of the unhealthy lifestyle and rising stress levels among the population. Apart from the U.S., Canada has also highly contributed to the insomnia market’s growth in this region. Global Insomnia MarketThe objective of the report is to present a comprehensive analysis of the global Insomnia Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also helps in understanding the global Insomnia Market dynamic, structure by analyzing the market segments and project the global Insomnia Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Insomnia Market make the report investor’s guide.

Global Insomnia Market Scope: Inquire before buying

Global Insomnia Market

Global Insomnia Market, by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Global Insomnia Market Key Players

• Astellas • Biocodex S A • Consumer Healthcare Inc. • Dainippon Sumitomo • ECR Pharmaceuticals • Eisai Co. • Flynn Pharma • Johnson and Johnson • Meda Consumer Healthcare Inc. • Merck and Co. Inc. • Neurim • Pernix Therapeutics • Pfizer Inc • Purdue Pharma L.P. • Sanofi Pasteur • SkyePharma • Takeda Pharmaceutical Company • Mallinckrodt • Galt Pharmaceuticals, LLC. • Sumitomo Dainippon Pharma Co., Ltd. • Teva Pharmaceutical Industries Ltd. • Vanda Pharmaceuticals

Frequently Asked Questions:

1] What segments are covered in Insomnia Market report? Ans.The segments covered in Insomnia Market report are based on Prescription Sleep Aids, Over-the-Counter Sleep Aids, and Non-pharmacological Treatment. 2] Which region is expected to hold the highest share in the global Insomnia Market? Ans. North America is expected to hold the highest share in the global Insomnia Market. 3] What is the market size of global Insomnia Market by 2027? Ans. The market size of global Insomnia Market by 2027 is US $ 6.43 Bn. 4] Who are the top key players in the global Insomnia Market? Ans. Astellas, Biocodex S A, Consumer Healthcare Inc., Dainippon Sumitomo, ECR Pharmaceuticals, and Eisai Co. are the top key players in the global Insomnia Market. 5] What was the market size of global Insomnia Market in 2020? Ans.The market size of global Insomnia Market in 2020 was US $ 4.82 Bn. 6] By Non-pharmacological Treatment, What segments are covered in Insomnia Market report? Ans. The segments covered in Insomnia Market report by Non-pharmacological Treatment, are Cognitive Behavioral Therapy for Insomnia (CBTI), Hypnotherapy and Other Alternative Therapies.
Insomnia Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Insomnia Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Insomnia Market Analysis and Forecast 6.1. Global Insomnia Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Insomnia Market Analysis and Forecast, by Over-the-Counter Sleep Aids 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 7.4. Global Insomnia Market Size (US$ Bn) Forecast, by Over-the-Counter Sleep Aids 7.5. Global Insomnia Market Analysis, by Over-the-Counter Sleep Aids 7.6. Global Insomnia Market Attractiveness Analysis, by Over-the-Counter Sleep Aids 8. Global Insomnia Market Analysis and Forecast, Non-pharmacological Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Insomnia Market Value Share Analysis, Non-pharmacological Treatment 8.4. Global Insomnia Market Size (US$ Bn) Forecast, Non-pharmacological Treatment 8.5. Global Insomnia Market Analysis, Non-pharmacological Treatment 8.6. Global Insomnia Market Attractiveness Analysis, Non-pharmacological Treatment 9. Global Insomnia Market Analysis and Forecast, by Prescription Sleep Aids 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Insomnia Market Value Share Analysis, by Prescription Sleep Aids 9.4. Global Insomnia Market Size (US$ Bn) Forecast, by Prescription Sleep Aids 9.5. Global Insomnia Market Analysis, by Prescription Sleep Aids 9.6. Global Insomnia Market Attractiveness Analysis, by Prescription Sleep Aids 10. Global Insomnia Market Analysis, by Region 10.1. Global Insomnia Market Value Share Analysis, by Region 10.2. Global Insomnia Market Size (US$ Bn) Forecast, by Region 10.3. Global Insomnia Market Attractiveness Analysis, by Region 11. North America Insomnia Market Analysis 11.1. Key Findings 11.2. North America Insomnia Market Overview 11.3. North America Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 11.4. North America Insomnia Market Forecast, by Over-the-Counter Sleep Aids 11.4.1.1. Antihistamines 11.4.1.2. Melatonin 11.4.1.3. Valerian Roots 11.4.1.4. Other Herbal & Dietary Supplements 11.5. North America Insomnia Market Value Share Analysis, Non-pharmacological Treatment 11.6. North America Insomnia Market Forecast, Non-pharmacological Treatment 11.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 11.6.2. Hypnotherapy 11.6.3. Other Alternative Therapies 11.7. North America Insomnia Market Value Share Analysis, by Prescription Sleep Aids 11.8. North America Insomnia Market Forecast, by Prescription Sleep Aids 11.8.1. Non-benzodiazepines 11.8.2. Benzodiazepines 11.8.3. Orexin Antagonists 11.8.4. Melatonin Receptor Antagonists 11.8.5. Other Prescription Sleep Aids 11.9. North America Insomnia Market Value Share Analysis, by Country 11.10. North America Insomnia Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Insomnia Market Analysis, by Country 11.12. U.S. Insomnia Market Forecast, by Over-the-Counter Sleep Aids 11.12.1.1. Antihistamines 11.12.1.2. Melatonin 11.12.1.3. Valerian Roots 11.12.1.4. Other Herbal & Dietary Supplements 11.13. U.S. Insomnia Market Forecast, Non-pharmacological Treatment 11.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 11.13.2. Hypnotherapy 11.13.3. Other Alternative Therapies 11.14. U.S. Insomnia Market Forecast, by Prescription Sleep Aids 11.14.1.1. Non-benzodiazepines 11.14.1.2. Benzodiazepines 11.14.1.3. Orexin Antagonists 11.14.1.4. Melatonin Receptor Antagonists 11.14.1.5. Other Prescription Sleep Aids 11.15. Canada Insomnia Market Forecast, by Over-the-Counter Sleep Aids 11.15.1.1. Antihistamines 11.15.1.2. Melatonin 11.15.1.3. Valerian Roots 11.15.1.4. Other Herbal & Dietary Supplements 11.16. Steel Canada Insomnia Market Forecast, Non-pharmacological Treatment 11.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 11.16.2. Hypnotherapy 11.16.3. Others2 11.17. Canada Insomnia Market Forecast, by Prescription Sleep Aids 11.17.1. Non-benzodiazepines 11.17.2. Benzodiazepines 11.17.3. Orexin Antagonists 11.17.4. Melatonin Receptor Antagonists 11.17.5. Other Prescription Sleep Aids 11.18. North America Insomnia Market Attractiveness Analysis 11.18.1. By Over-the-Counter Sleep Aids 11.18.2. Non-pharmacological Treatment 11.18.3. By Prescription Sleep Aids 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Insomnia Market Analysis 12.1. Key Findings 12.2. Europe Insomnia Market Overview 12.3. Europe Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 12.4. Europe Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.4.1.1. Antihistamines 12.4.1.2. Melatonin 12.4.1.3. Valerian Roots 12.4.1.4. Other Herbal & Dietary Supplements 12.5. Europe Insomnia Market Value Share Analysis, Non-pharmacological Treatment 12.6. Europe Insomnia Market Forecast, Non-pharmacological Treatment 12.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.6.2. Hypnotherapy 12.6.3. Other Alternative Therapies 12.7. Europe Insomnia Market Value Share Analysis, by Prescription Sleep Aids 12.8. Europe Insomnia Market Forecast, by Prescription Sleep Aids 12.8.1. Non-benzodiazepines 12.8.2. Benzodiazepines 12.8.3. Orexin Antagonists 12.8.4. Melatonin Receptor Antagonists 12.8.5. Other Prescription Sleep Aids 12.9. Europe Insomnia Market Value Share Analysis, by Country 12.10. Europe Insomnia Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Insomnia Market Analysis, by Country 12.12. Germany Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.12.1.1. Antihistamines 12.12.1.2. Melatonin 12.12.1.3. Valerian Roots 12.12.1.4. Other Herbal & Dietary Supplements 12.13. Germany Insomnia Market Forecast, Non-pharmacological Treatment 12.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.13.2. Hypnotherapy 12.13.3. Other Alternative Therapies 12.14. Germany Insomnia Market Forecast, by Prescription Sleep Aids 12.14.1. Non-benzodiazepines 12.14.2. Benzodiazepines 12.14.3. Orexin Antagonists 12.14.4. Melatonin Receptor Antagonists 12.14.5. Other Prescription Sleep Aids 12.15. U.K. Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.15.1.1. Antihistamines 12.15.1.2. Melatonin 12.15.1.3. Valerian Roots 12.15.1.4. Other Herbal & Dietary Supplements 12.16. U.K. Insomnia Market Forecast, Non-pharmacological Treatment 12.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.16.2. Hypnotherapy 12.16.3. Other Alternative Therapies 12.17. U.K. Insomnia Market Forecast, by Prescription Sleep Aids 12.17.1. Non-benzodiazepines 12.17.2. Benzodiazepines 12.17.3. Orexin Antagonists 12.17.4. Melatonin Receptor Antagonists 12.17.5. Other Prescription Sleep Aids 12.18. France Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.18.1.1. Antihistamines 12.18.1.2. Melatonin 12.18.1.3. Valerian Roots 12.18.1.4. Other Herbal & Dietary Supplements 12.19. France Insomnia Market Forecast, Non-pharmacological Treatment 12.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.19.2. Hypnotherapy 12.19.3. Other Alternative Therapies 12.20. France Insomnia Market Forecast, by Prescription Sleep Aids 12.20.1. Non-benzodiazepines 12.20.2. Benzodiazepines 12.20.3. Orexin Antagonists 12.20.4. Melatonin Receptor Antagonists 12.20.5. Other Prescription Sleep Aids 12.21. Italy Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.21.1.1. Antihistamines 12.21.1.2. Melatonin 12.21.1.3. Valerian Roots 12.21.1.4. Other Herbal & Dietary Supplements 12.22. Italy Insomnia Market Forecast, Non-pharmacological Treatment 12.22.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.22.2. Hypnotherapy 12.22.3. Other Alternative Therapies 12.23. Italy Insomnia Market Forecast, by Prescription Sleep Aids 12.23.1. Dental clinics 12.23.2. Hospital Non-benzodiazepines 12.23.3. Benzodiazepines 12.23.4. Orexin Antagonists 12.23.5. Melatonin Receptor Antagonists 12.23.6. Other Prescription Sleep Aids 12.24. Spain Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.24.1.1. Antihistamines 12.24.1.2. Melatonin 12.24.1.3. Valerian Roots 12.24.1.4. Other Herbal & Dietary Supplements 12.25. Spain Insomnia Market Forecast, Non-pharmacological Treatment 12.25.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.25.2. Hypnotherapy 12.25.3. Other Alternative Therapies 12.26. Spain Insomnia Market Forecast, by Prescription Sleep Aids 12.26.1. Non-benzodiazepines 12.26.2. Benzodiazepines 12.26.3. Orexin Antagonists 12.26.4. Melatonin Receptor Antagonists 12.26.5. Other Prescription Sleep Aids 12.27. Rest of Europe Insomnia Market Forecast, by Over-the-Counter Sleep Aids 12.27.1.1. Antihistamines 12.27.1.2. Melatonin 12.27.1.3. Valerian Roots 12.27.1.4. Other Herbal & Dietary Supplements 12.28. Rest of Europe Insomnia Market Forecast, Non-pharmacological Treatment 12.28.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 12.28.2. Hypnotherapy 12.28.3. Other Alternative Therapies 12.29. Rest Of Europe Insomnia Market Forecast, by Prescription Sleep Aids 12.29.1. Non-benzodiazepines 12.29.2. Benzodiazepines 12.29.3. Orexin Antagonists 12.29.4. Melatonin Receptor Antagonists 12.29.5. Other Prescription Sleep Aids 12.30. Europe Insomnia Market Attractiveness Analysis 12.30.1. By Over-the-Counter Sleep Aids 12.30.2. Non-pharmacological Treatment 12.30.3. By Prescription Sleep Aids 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Insomnia Market Analysis 13.1. Key Findings 13.2. Asia Pacific Insomnia Market Overview 13.3. Asia Pacific Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 13.4. Asia Pacific Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.4.1.1. Antihistamines 13.4.1.2. Melatonin 13.4.1.3. Valerian Roots 13.4.1.4. Other Herbal & Dietary Supplements 13.5. Asia Pacific Insomnia Market Value Share Analysis, Non-pharmacological Treatment 13.6. Asia Pacific Insomnia Market Forecast, Non-pharmacological Treatment 13.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.6.2. Hypnotherapy 13.6.3. Others2 13.7. Asia Pacific Insomnia Market Value Share Analysis, by Prescription Sleep Aids 13.8. Asia Pacific Insomnia Market Forecast, by Prescription Sleep Aids 13.8.1. Non-benzodiazepines 13.8.2. Benzodiazepines 13.8.3. Orexin Antagonists 13.8.4. Melatonin Receptor Antagonists 13.8.5. Other Prescription Sleep Aids 13.9. Asia Pacific Insomnia Market Value Share Analysis, by Country 13.10. Asia Pacific Insomnia Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Insomnia Market Analysis, by Country 13.12. China Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.12.1.1. Antihistamines 13.12.1.2. Melatonin 13.12.1.3. Valerian Roots 13.12.1.4. Other Herbal & Dietary Supplements 13.13. China Insomnia Market Forecast, Non-pharmacological Treatment 13.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.13.2. Hypnotherapy 13.13.3. Others2 13.14. China Insomnia Market Forecast, by Prescription Sleep Aids 13.14.1. Non-benzodiazepines 13.14.2. Benzodiazepines 13.14.3. Orexin Antagonists 13.14.4. Melatonin Receptor Antagonists 13.14.5. Other Prescription Sleep Aids 13.15. India Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.15.1.1. Antihistamines 13.15.1.2. Melatonin 13.15.1.3. Valerian Roots 13.15.1.4. Other Herbal & Dietary Supplements 13.16. India Insomnia Market Forecast, Non-pharmacological Treatment 13.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.16.2. Hypnotherapy 13.16.3. Other Alternative Therapies 13.17. India Insomnia Market Forecast, by Prescription Sleep Aids 13.17.1. Non-benzodiazepines 13.17.2. Benzodiazepines 13.17.3. Orexin Antagonists 13.17.4. Melatonin Receptor Antagonists 13.17.5. Other Prescription Sleep Aids 13.18. Japan Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.18.1.1. Antihistamines 13.18.1.2. Melatonin 13.18.1.3. Valerian Roots 13.18.1.4. Other Herbal & Dietary Supplements 13.19. Japan Insomnia Market Forecast, Non-pharmacological Treatment 13.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.19.2. Hypnotherapy 13.19.3. Others2 13.20. Japan Insomnia Market Forecast, by Prescription Sleep Aids 13.20.1. Non-benzodiazepines 13.20.2. Benzodiazepines 13.20.3. Orexin Antagonists 13.20.4. Melatonin Receptor Antagonists 13.20.5. Other Prescription Sleep Aids l 13.21. ASEAN Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.21.1.1. Antihistamines 13.21.1.2. Melatonin 13.21.1.3. Valerian Roots 13.21.1.4. Other Herbal & Dietary Supplements 13.22. ASEAN Insomnia Market Forecast, Non-pharmacological Treatment 13.22.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.22.2. Hypnotherapy 13.22.3. Other Alternative Therapies 13.23. ASEAN Insomnia Market Forecast, by Prescription Sleep Aids 13.23.1. Non-benzodiazepines 13.23.2. Benzodiazepines 13.23.3. Orexin Antagonists 13.23.4. Melatonin Receptor Antagonists 13.23.5. Other Prescription Sleep Aids 13.24. Rest of Asia Pacific Insomnia Market Forecast, by Over-the-Counter Sleep Aids 13.24.1.1. Antihistamines 13.24.1.2. Melatonin 13.24.1.3. Valerian Roots 13.24.1.4. Other Herbal & Dietary Supplements 13.25. Rest of Asia Pacific Insomnia Market Forecast, Non-pharmacological Treatment 13.25.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 13.25.2. Hypnotherapy 13.25.3. Other Alternative Therapies 13.26. Rest of Asia Pacific Insomnia Market Forecast, by Prescription Sleep Aids 13.26.1. Non-benzodiazepines 13.26.2. Benzodiazepines 13.26.3. Orexin Antagonists 13.26.4. Melatonin Receptor Antagonists 13.26.5. Other Prescription Sleep Aids 13.27. Asia Pacific Insomnia Market Attractiveness Analysis 13.27.1. By Over-the-Counter Sleep Aids 13.27.2. Non-pharmacological Treatment 13.27.3. By Prescription Sleep Aids 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Insomnia Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Insomnia Market Overview 14.3. Middle East & Africa Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 14.4. Middle East & Africa Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.4.1.1. Antihistamines 14.4.1.2. Melatonin 14.4.1.3. Valerian Roots 14.4.1.4. Other Herbal & Dietary Supplements 14.5. Middle East & Africa Insomnia Market Value Share Analysis, Non-pharmacological Treatment 14.6. Middle East & Africa Insomnia Market Forecast, Non-pharmacological Treatment 14.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.6.2. Hypnotherapy 14.6.3. Others2 14.7. Middle East & Africa Insomnia Market Value Share Analysis, by Prescription Sleep Aids 14.8. Middle East & Africa Insomnia Market Forecast, by Prescription Sleep Aids 14.8.1. Non-benzodiazepines 14.8.2. Benzodiazepines 14.8.3. Orexin Antagonists 14.8.4. Melatonin Receptor Antagonists 14.8.5. Other Prescription Sleep Aids 14.9. Middle East & Africa Insomnia Market Value Share Analysis, by Country 14.10. Middle East & Africa Insomnia Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Insomnia Market Analysis, by Country 14.12. GCC Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.12.1.1. Antihistamines 14.12.1.2. Melatonin 14.12.1.3. Valerian Roots 14.12.1.4. Other Herbal & Dietary Supplements 14.13. GCC Insomnia Market Forecast, Non-pharmacological Treatment 14.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.13.2. Hypnotherapy 14.13.3. Other Alternative Therapies 14.14. GCC Insomnia Market Forecast, by Prescription Sleep Aids 14.14.1. Non-benzodiazepines 14.14.2. Benzodiazepines 14.14.3. Orexin Antagonists 14.14.4. Melatonin Receptor Antagonists 14.14.5. Other Prescription Sleep Aids 14.15. South Africa Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.15.1.1. Antihistamines 14.15.1.2. Melatonin 14.15.1.3. Valerian Roots 14.15.1.4. Other Herbal & Dietary Supplements 14.16. South Africa Insomnia Market Forecast, Non-pharmacological Treatment 14.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.16.2. Hypnotherapy 14.16.3. Other Alternative Therapies 14.17. South Africa Insomnia Market Forecast, by Prescription Sleep Aids 14.17.1. Non-benzodiazepines 14.17.2. Benzodiazepines 14.17.3. Orexin Antagonists 14.17.4. Melatonin Receptor Antagonists 14.17.5. Other Prescription Sleep Aids 14.18. Rest of Middle East & Africa Insomnia Market Forecast, by Over-the-Counter Sleep Aids 14.18.1.1. Antihistamines 14.18.1.2. Melatonin 14.18.1.3. Valerian Roots 14.18.1.4. Other Herbal & Dietary Supplements 14.19. Rest of Middle East & Africa Insomnia Market Forecast, Non-pharmacological Treatment 14.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 14.19.2. Hypnotherapy 14.19.3. Others2 14.20. Rest of Middle East & Africa Insomnia Market Forecast, by Prescription Sleep Aids 14.20.1. Non-benzodiazepines 14.20.2. Benzodiazepines 14.20.3. Orexin Antagonists 14.20.4. Melatonin Receptor Antagonists 14.20.5. Other Prescription Sleep Aids 14.21. Middle East & Africa Insomnia Market Attractiveness Analysis 14.21.1. By Over-the-Counter Sleep Aids 14.21.2. Non-pharmacological Treatment 14.21.3. By Prescription Sleep Aids 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Insomnia Market Analysis 15.1. Key Findings 15.2. South America Insomnia Market Overview 15.3. South America Insomnia Market Value Share Analysis, by Over-the-Counter Sleep Aids 15.4. South America Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.4.1.1. Antihistamines 15.4.1.2. Melatonin 15.4.1.3. Valerian Roots 15.4.1.4. Other Herbal & Dietary Supplements 15.5. South America Insomnia Market Value Share Analysis, Non-pharmacological Treatment 15.6. South America Insomnia Market Forecast, Non-pharmacological Treatment 15.6.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.6.2. Hypnotherapy 15.6.3. Other Alternative Therapies 15.7. South America Insomnia Market Value Share Analysis, by Prescription Sleep Aids 15.8. South America Insomnia Market Forecast, by Prescription Sleep Aids 15.8.1. Non-benzodiazepines 15.8.2. Benzodiazepines 15.8.3. Orexin Antagonists 15.8.4. Melatonin Receptor Antagonists 15.8.5. Other Prescription Sleep Aids 15.9. South America Insomnia Market Value Share Analysis, by Country 15.10. South America Insomnia Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Insomnia Market Analysis, by Country 15.12. Brazil Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.12.1.1. Antihistamines 15.12.1.2. Melatonin 15.12.1.3. Valerian Roots 15.12.1.4. Other Herbal & Dietary Supplements 15.13. Brazil Insomnia Market Forecast, Non-pharmacological Treatment 15.13.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.13.2. Hypnotherapy 15.13.3. Other Alternative Therapies 15.14. Brazil Insomnia Market Forecast, by Prescription Sleep Aids 15.14.1. Non-benzodiazepines 15.14.2. Benzodiazepines 15.14.3. Orexin Antagonists 15.14.4. Melatonin Receptor Antagonists 15.14.5. Other Prescription Sleep Aids 15.15. Mexico Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.15.1.1. Antihistamines 15.15.1.2. Melatonin 15.15.1.3. Valerian Roots 15.15.1.4. Other Herbal & Dietary Supplements 15.16. Mexico Insomnia Market Forecast, Non-pharmacological Treatment 15.16.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.16.2. Hypnotherapy 15.16.3. Other Alternative Therapies 15.17. Mexico Insomnia Market Forecast, by Prescription Sleep Aids 15.17.1. Non-benzodiazepines 15.17.2. Benzodiazepines 15.17.3. Orexin Antagonists 15.17.4. Melatonin Receptor Antagonists 15.17.5. Other Prescription Sleep Aids 15.18. Rest of South America Insomnia Market Forecast, by Over-the-Counter Sleep Aids 15.18.1.1. Antihistamines 15.18.1.2. Melatonin 15.18.1.3. Valerian Roots 15.18.1.4. Other Herbal & Dietary Supplements 15.19. Rest of South America Insomnia Market Forecast, Non-pharmacological Treatment 15.19.1. Cognitive Behavioral Therapy for Insomnia (CBTI) 15.19.2. Hypnotherapy 15.19.3. Other Alternative Therapies 15.20. Rest of South America Insomnia Market Forecast, by Prescription Sleep Aids 15.20.1. Non-benzodiazepines 15.20.2. Benzodiazepines 15.20.3. Orexin Antagonists 15.20.4. Melatonin Receptor Antagonists 15.20.5. Other Prescription Sleep Aids 15.21. South America Insomnia Market Attractiveness Analysis 15.21.1. By Over-the-Counter Sleep Aids 15.21.2. Non-pharmacological Treatment 15.21.3. By Prescription Sleep Aids 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Biocodex S A 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Astellas 16.3.3. Biocodex S A 16.3.4. Consumer Healthcare Inc. 16.3.5. Dainippon Sumitomo 16.3.6. ECR Pharmaceuticals 16.3.7. Eisai Co. 16.3.8. Flynn Pharma 16.3.9. Johnson and Johnson 16.3.10. Meda Consumer Healthcare Inc. 16.3.11. Merck and Co. Inc. 16.3.12. Neurim 16.3.13. Pernix Therapeutics 16.3.14. Pfizer Inc 16.3.15. Purdue Pharma L.P. 16.3.16. Sanofi Pasteur 16.3.17. SkyePharma 16.3.18. Takeda Pharmaceutical Company 16.3.19. Mallinckrodt 16.3.20. Galt Pharmaceuticals, LLC. 16.3.21. Sumitomo Dainippon Pharma Co., Ltd. 16.3.22. Teva Pharmaceutical Industries Ltd. 16.3.23. Vanda Pharmaceuticals 17. Primary Key Insights

About This Report

Report ID37228
Category Healthcare
Published DateNov 2019
Updated DateSep 2021
Contact Us